ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Arthur Upton New Name In Director Race; Califano Meets With Prospects

May 6, 1977

SAIC Begins Transition Of Frederick Operations From Incumbent PRI

March 17, 1995

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

April 16, 1999

NCI Publishes Report On Pancreatic Cancer

March 7, 2014

Group Chairmen Object To “Directive” Language In Proposed Intergroup Study Guidelines

January 13, 1984

Former FDA Commissioner Lester Crawford Pleads Guilty to Filing False Reports About His Ownership of Stocks in Health, Food, Biotech Companies.

October 20, 2006